-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Protagenic Therapeutics (OTCMKTS:PTIX) Stock Price Passes Below 200-Day Moving Average of $0.80
Protagenic Therapeutics (OTCMKTS:PTIX) Stock Price Passes Below 200-Day Moving Average of $0.80
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.
Protagenic Therapeutics Stock Performance
The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.
Get Protagenic Therapeutics alerts:Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.
About Protagenic Therapeutics
(Get Rating)Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Featured Articles
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.
在週一的交易中，普羅吉治療公司(OTCMKTS：PTIX-GET Rating)的股價跌破了200日移動均線。該股的200日移動均線為0.80美元，最低交易價格為0.62美元。普羅吉治療公司的股票最新報0.65美元，總成交量為61,694股。
Protagenic Therapeutics Stock Performance
普羅地亞治療類股業績
The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.
該股的50日簡單移動均線為0.68美元，200日簡單移動均線為0.80美元。該公司的債務權益比為0.04，流動比率為19.47，速動比率為19.47。
Institutional Investors Weigh In On Protagenic Therapeutics
機構投資者對普羅替尼治療公司的看法
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.
一家機構投資者最近提高了其在普羅吉治療公司股票的頭寸。復興科技有限責任公司最近提交給美國證券交易委員會的文件顯示，該公司第一季度將其在普羅吉治療公司(OTCMKTS：PTIX-GET Rating)的持股比例提高了69.2%。在此期間，該公司額外收購了41,800股生物技術公司的股票，目前持有102,200股。在最近一次報告所述期間結束時，復興技術有限責任公司擁有普羅吉治療公司約0.59%的股份，價值8.3萬美元。該公司11.09%的股票目前由機構投資者和對衝基金持有。
About Protagenic Therapeutics
關於前列腺素治療學
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
前列基因治療公司是一家生物製藥公司，致力於發現和開發治療與壓力相關的神經精神和情緒障礙的療法。它的先導化合物是PT00114，這是Teneurin羧基末端相關肽的合成形式，Teneurin羧基末端相關肽是一種內源性大腦信號肽，可以抑制過度活躍的應激反應。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
- 免費獲取StockNews.com關於前列腺素治療(PTIX)的研究報告
- MarketBeat播客：股票投資組合中的夢幻足球策略
- 你應該在怪物需求之前買入這些銅庫存嗎？
- 三隻能夠渡過風暴般的衰退的工業股票
- 牀上洗澡和肉食之外：Bynd是下一個大空頭嗎？
- Denbury因出售傳言而上漲，但落後於其他能源公司
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅汀治療日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊，收到對Protag Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧